Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Nephrology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to Nephrology Articles

Monday 3rd May, 2004

   
 
Raising the target hematocrit/hemoglobin levels to near normal values has beneficial effects for dialysis patients.
 

tellfrnd.gif (30x26 -- 1330 bytes)send to a friend
 
prntfrnd.gif (30x26 -- 1309 bytes)printer friendly version

  Related
 
 

Adequacy of dialysis

 

A prospective study, published in this month's edition of Journal of the American Society of Nephrology, was set to evaluate the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin.

Erythropoietin

Erythropoietin (or EPO) is a glycoprotein hormone produced in the human kidney. It has been found that it is also produced in the liver (mainly in the fetus), the brain and uterus. Erythropoietin production is stimulated by the reduction of oxygen in the renal arteries.

It acts by binding to the specific erythropoietin receptor (EpoR). Erythropoietin produced in the kidney/bone marrow stimulates stem cells in the bone marrow to increase production of erythrocytes (red blood cells). The role of paracrine erythropoietin in the brain and uterus is not fully elucidated.

Recombinant human erythropoietin

The gene which encodes Erythropoietin production was cloned in 1985 and has been successfully implanted in guinea pigs in order to produce artificial Erythropoietin (also known as recombinant human erythropoietin) in the form of Epoetin a drug present on the market.

Patients with renal failure have low levels of erythropoietin which in turn leads to the chronic anemia that accompanies renal failure. The use of recombinant EPO has essentially eliminated anemia as a major cause of morbidity in dialysis patients. In the United States, where almost 90 percent of chronically dialyzed patients currently receive EPO.

The currently recommended target hemoglobin concentration ranges between 10 and 12 g/dL (original FDA approved range), The attainment of this narrow range of target hemoglobin levels may be difficult in standard clinical practice.

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


Indications

EPO should be administered to any dialysis patient with symptoms attributable at least in part to anemia. These include fatigue, decreased exercise tolerance, congestive heart failure, and angina. EPO should not be started until iron status has been evaluated. Iron supplements should be given first in patients with evidence of iron deficiency (plasma ferritin concentration less than 100 ng/mL or transferrin saturation below 20 percent). Other causes of anemia should also be excluded and hypertension corrected before EPO therapy is begun.

Raising the hemoglobin target

One would think that using EPO to raise the target hemoglobin to normal or near normal values would be even more beneficial. However, some studies have suggested it may even be harmful. In a retrospective study of nearly 100,000 hemodialysis patients in the United States, patients with a hematocrit of less than 30 percent had a 12 to 33 percent higher risk of death compared to those with hematocrits of 30 to 33 percent. An additional reduction in risk of 4 percent was observed among the group with hematocrits of 33 to 36 percent. In a prospective study patients were randomly assigned to a target hematocrit of either 42 or 30 percent. The primary end points were death or first nonfatal myocardial infarction. The study was terminated after 29 months for two reasons: the group targeted to normal values had a higher mortality which was approaching, but had not yet attained, statistical significance; and it was extremely unlikely (as determined statistically) that benefits would eventually be realized with higher target values if the study were to continue.

Whether the target hematocrit/hemoglobin levels may be extended to near normal values among other patient groups awaits the results of ongoing and future studies. There is limited evidence that higher target values may be safe and beneficial among dialysis patients without diabetes, heart failure, coronary heart disease, or cerebrovascular disease.

Study details

The current study is part of the ongoing effort to elucidate the value of raising the hemoglobin target in dialysis patients. Partial correction of anemia by erythropoietin improves hemodialysis (HD)-associated immunosuppression. The authors prospectively compared the immune function of HD patients with congestive heart failure or ischemic heart disease on erythropoietin therapy randomized to normal versus anemic blood hemoglobin concentration. Delayed-type hypersensitivity, CD4 and CD8 counts, anti?tetanus toxoid antibody levels taken after vaccination, erythrocyte complement receptor 1 expression, and lymphocyte proliferative responsiveness were taken as measures of their immune status. The observation period was 1 yr, and the trial was open label. Their data suggest that certain aspects of immune function, particularly delayed-type hypersensitivity, may be improved in HD patients by normalization of hemoglobin through the administration of increased doses of erythropoietin.

The most common side effects of EPO treatment are:

  • Hypertension
  • Headache
  • Influenza-like syndrome
  • Increase in the risk of thrombotic events
  • Pure red cell aplasia

References

Renato M.B. Roman, Peter I. Lobo, Ronald P. Taylor, David A. Goodkin, John LaBrecque, Kathy L. Powers and W. Kline Bolton. Prospective Study of the Immune Effects of Normalizing the Hemoglobin Concentration in Hemodialysis Patients Who Receive Recombinant Human Erythropoietin. J Am Soc Nephrol 15:1339-1346, 2004.

 

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.